{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:05:50Z","timestamp":1789704350656,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Stem Cell Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.stemcr.2024.102395","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:34:14Z","timestamp":1737646454000},"page":"102395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A novel rapalog shows improved safety vs. efficacy in a human organoid model of polycystic kidney disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Ramila E.","family":"Gulieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvaneh","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-7383","authenticated-orcid":false,"given":"Benjamin S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.stemcr.2024.102395_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/acel.12405","article-title":"Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system","volume":"15","author":"Arriola Apelo","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.stemcr.2024.102395_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"Breuleux","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.stemcr.2024.102395_bib3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.stemcr.2024.102395_bib4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nmat4994","article-title":"Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease","volume":"16","author":"Cruz","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.stemcr.2024.102395_bib5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","article-title":"High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping","volume":"22","author":"Czerniecki","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stemcr.2024.102395_bib6","doi-asserted-by":"crossref","first-page":"F625","DOI":"10.1152\/ajprenal.00400.2021","article-title":"Physiology assays in human kidney organoids","volume":"322","author":"Freedman","year":"2022","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.stemcr.2024.102395_bib7","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1038\/ncomms9715","article-title":"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids","volume":"6","author":"Freedman","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stemcr.2024.102395_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ndt\/gfs519","article-title":"mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open","volume":"28","author":"Jardine","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.stemcr.2024.102395_bib9","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.stemcr.2024.102395_bib10","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1038\/s41467-022-35537-2","article-title":"Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stemcr.2024.102395_bib11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/ki.1992.184","article-title":"In\u00a0vitro formation and expansion of cysts derived from human renal cortex epithelial cells","volume":"41","author":"Neufeld","year":"1992","journal-title":"Kidney Int."},{"key":"10.1016\/j.stemcr.2024.102395_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.stemcr.2024.06.007","article-title":"Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility","volume":"19","author":"Pamies","year":"2024","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stemcr.2024.102395_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.stemcr.2024.102395_bib14","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/s41467-019-11174-0","article-title":"A novel rapamycin analog is highly selective for mTORC1 in\u00a0vivo","volume":"10","author":"Schreiber","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stemcr.2024.102395_bib15","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: the discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.stemcr.2024.102395_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.stemcr.2024.102395_bib17","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stemcr.2024.102395_bib18","first-page":"489","article-title":"Tolvaptan in Later-Stage Polycystic Kidney Disease","volume":"378","author":"Torres","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.stemcr.2024.102395_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.stem.2022.06.005","article-title":"A scalable organoid model of human autosomal dominant polycystic kidney disease for disease mechanism and drug discovery","volume":"29","author":"Tran","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stemcr.2024.102395_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening","volume":"26","author":"Trelinska","year":"2015","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.stemcr.2024.102395_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2013.00165","article-title":"The Paradox of Akt-mTOR Interactions","volume":"3","author":"Vadlakonda","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.stemcr.2024.102395_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.stem.2024.03.005","article-title":"Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease","volume":"31","author":"Vishy","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stemcr.2024.102395_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.stemcr.2024.102395_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.stemcr.2024.102395_bib25","doi-asserted-by":"crossref","first-page":"F1597","DOI":"10.1152\/ajprenal.00430.2009","article-title":"Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease","volume":"297","author":"Wu","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.stemcr.2024.102395_bib26","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41588-022-01202-z","article-title":"Adult human kidney organoids originate from CD24(+) cells and represent an advanced model for adult polycystic kidney disease","volume":"54","author":"Xu","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.stemcr.2024.102395_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.stemcr.2024.102395_bib28","series-title":"Clinical trials in autosomal dominant polycystic kidney disease","first-page":"109","author":"Yu","year":"2015"}],"container-title":["Stem Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213671124003552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213671124003552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T01:52:02Z","timestamp":1740707522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213671124003552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2213671124003552"],"URL":"https:\/\/doi.org\/10.1016\/j.stemcr.2024.102395","relation":{},"ISSN":["2213-6711"],"issn-type":[{"value":"2213-6711","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel rapalog shows improved safety vs. efficacy in a human organoid model of polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Stem Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.stemcr.2024.102395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Stem Cell Research.","name":"copyright","label":"Copyright"}],"article-number":"102395"}}